Conference Correspondent

Pragmatic setting administration of the all-oral combination of pomalidomide plus cyclophosphamide/dexamethasone (POMCIDEX) is a manageable, effective treatment option for patients with relapsed/refractory multiple myeloma. Read More ›

Based on early results of a dose-escalation study, teclistamab demonstrated an overall response rate of 67% at the highest dose, as well as reasonable tolerability with low incidence of high-grade cytokine release syndrome in patients with advanced relapsed/refractory multiple myeloma. Read More ›

Isatuximab plus carfilzomib/dexamethasone (IKEMA study) shows promising efficacy and tolerable safety in prolonging progression-free survival compared with carfilzomib/dexamethasone alone in the treatment of patients with RRMM. Read More ›

Efficacy and toxicity outcome measures with daratumumab added to carfilzomib/dexamethasone were consistent across subgroups within the CANDOR trial, regardless of lenalidomide- or bortezomib-refractory status or number of previous treatments. Read More ›

A systematic literature review to investigate evidence for therapies in patients with RRMM suggests there is limited published efficacy data available to support treatment options for heavily pretreated patients with RRMM. Read More ›

Idecabtagene vicleucel resulted in an overall response rate of 73% and demonstrated a tolerable safety profile in heavily pretreated patients who were refractory to their last regimen in the KarMMa trial. Read More ›

An update from the phase 1b/2 CARTITUDE study reveals early, deep, and durable responses and a manageable safety profile from treatment of patients with advanced RRMM with JNJ-4528 CAR T-cells. Read More ›

Ixazomib provided as part of an early access program in Europe resulted in a 58% overall response rate in an observational multicenter cohort study (UVEA-IXA) supporting the effectiveness of the drug in a real-world setting. Read More ›

In the GMMG-Concept trial, the addition of isatuximab to carfilzomib/lenalidomide/ dexamethasone in newly diagnosed high-risk patients with multiple myeloma led to an approximately 90% rate of very good partial response or better with manageable toxicity. Read More ›

Post-induction ixazomib as maintenance therapy in patients newly diagnosed with multiple myeloma not treated with front-line stem-cell transplantation (TOURMALINE-MM4 trial) resulted in median progression-free survival of 17.4 months with tolerable safety. Read More ›

Page 1 of 16

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: